Mergers & Acquisitions - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

226 to 250 of 255 results

uniQure to acquire Amsterdam Molecular Therapeutics business

19-02-2012

Netherlands-based human gene based therapies developer Amsterdam Molecular Therapeutics (Euronext: AMT)…

Amsterdam MolecularBiotechnologyMergers & AcquisitionsuniQure

Karo Bio drops eprotirome and split up plans

15-02-2012

There was a double-dose of bad news for Sweden’s Karo Bio (STO: KARO), which this week said it would…

BiotechnologyCardio-vasculareprotiromeKaro BioMergers & AcquisitionsPharmaceuticalRegulation

Biogen Idec in deal to buy Stromedix

15-02-2012

S biotech firm Biogen Idec (Nasdaq: BIIB) has entered into a definitive agreement to acquire Stromedix,…

Biogen IdecBiotechnologyMergers & AcquisitionsStromedix

Valeant bags another company, Eyetech

14-02-2012

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says that it has agreed…

BiotechnologyEyetechMacugenMergers & AcquisitionsOphthalmicsPharmaceuticalValeant Pharmaceuticals

Biotech deal-making off to a strong start in 2012, says Burrill

02-02-2012

Swiss drug major Roche's hostile $5.7 billion bid for the tools and sequencing systems company Illumina…

BiotechnologyFinancialLicensingMergers & AcquisitionsNorth America

Amgen to acquire US/German biotech firm

27-01-2012

Adding to the strong start this year for M&A activity in the Pharma/Biotech sector, USA-based Amgen (Nasdaq:…

AmgenBiotechnologyMergers & AcquisitionsMicrometOncology

Celgene to buy Avila; posts strong 4th-qtr results

27-01-2012

USA-based Celgene (Nasdaq: CELG) yesterday revealed that it has entered into a definitive merger deal…

Avila TherapeuticsBiotechnologyCelgeneFinancialMergers & AcquisitionsOncologyPharmaceutical

Global biotechnology market set to exceed $320 billion by 2015, says GIA

25-01-2012

The biotechnology industry was adversely affected by the global financial crisis, with several leading…

BiotechnologyGlobalMarkets & MarketingMergers & AcquisitionsResearch

Roche in epigenetics drug discovery collaboration

18-01-2012

USA-based Constellation Pharmaceuticals says that it has entered into a major strategic agreement with…

BiotechnologyConstellation PharmaceuticalsGenentechLicensingMergers & AcquisitionsOncologyPharmaceuticalRoche

2011 a bumper year for Pharma, Biotech and Generics M&A

11-01-2012

Although there were few multi-billion dollar deals, 2011 turned into a bumper year for the number of…

BiotechBiotechnologyGenericsMergers & AcquisitionsPharmaceutical

Pharmaceutical M&A deals in 2011

11-01-2012

Details for the 129 M&A announcements recorded by The Pharma Letter are provided in the full table

BiotechGenericsMergers & AcquisitionsPharmaceutical

RusNano to start production of vaccines and organogels

09-01-2012

Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

Smith & Nephew to spin-out biologics and clinical therapies unit

05-01-2012

Texas, USA-based venture capital firm Essex Woodlands has entered into a strategic partnership with the…

BiotechnologyBioventusMergers & AcquisitionsSmith & Nephew

Biotech predictions for 2012 from sector specialist Steven Burrill

03-01-2012

As 2011 drew to a close, Steven Burrill, chief executive of global life sciences financial services firm…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegulation

Actelion pulls out of Trophos option

13-12-2011

Switzerland-based Actelion (SIX: ATLN), Europe’s biggest biotech company, says that it has decided…

ActelionBiotechnologyLicensingMergers & AcquisitionsolesoximePharmaceuticalRare diseasesTrophos

US Biotech scores wins in November, despite global economic turmoil, says Burrill

04-12-2011

Economic and political worries in Europe and the USA fuelled another month of wild gyrations in the stock…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaResearch

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

22-11-2011

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Valeant to acquire Australia’s iNova for up to $946 million

22-11-2011

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has signed…

BiotechnologyiNovaMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Angiotech opts out of cardiovascular cell therapy program with Athersys

15-11-2011

Regenerative medicines firm Athersys (Nasdaq: ATHX) says that Canada’s Angiotech Pharmaceuticals…

AngiotechAthersysBiotechnologyFinancialLicensingMergers & Acquisitions

Karo Bio to spin off preclinical development

26-10-2011

In order to achieve better allocation of resources and competences, Swedish biotech firm Karo Bio (STO:…

BiotechnologyKaro BioMergers & AcquisitionsResearch

WuXi PharmaTech acquires China-based clinical services companies; ShangPharma buys Charles River research facility

25-10-2011

WuXi PharmaTech (NYSE: WX) says it has acquired MedKey Med-Tech Development and Jiecheng Med-Tech Development,…

BiotechnologyCharles River LaboratoriesMergers & AcquisitionsPharmaceuticalShangPharmaWuXi Apptec

GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports

18-10-2011

Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Angel Biotech proposes joint venture with Russia’s Materia Medica

18-10-2011

Scotland-based Angel Biotechnology (ABH: LON) saw its shares leap 20% to 0.28 pence on Monday after it…

Angel BiotechnologyBiotechnologyEuropeMateria MedicaMergers & Acquisitions

226 to 250 of 255 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top